- Capital Cube•3 days ago
Categories: Yahoo Finance Get free summary analysis Protalix Biotherapeutics, Inc. reports financial results for the quarter ended December 31, 2016. We analyze the earnings along side the following peers of Protalix Biotherapeutics, Inc. – Amicus Therapeutics, Inc., Pfizer Inc., Neurocrine Biosciences, Inc., Aviragen Therapeutics Inc and Teva Pharmaceutical Industries Limited Sponsored ADR (FOLD-US, PFE-US, NBIX-US, AVIR-US and TEVA-US) ... Read more (Read more...)
- GlobeNewswire•7 days ago
Current Cash is projected to Fund the Company through Three Clinical Trial Read-Outs and into 2019. CARMIEL, Israel, March 16, 2017-- Protalix BioTherapeutics, Inc., a biopharmaceutical company focused ...
- Accesswire•9 days ago
NEW YORK, NY / ACCESSWIRE / March 14, 2017 / The Biotech Sector is seeing the arrival of some new competitors, with one company continuing to overperform and another set to have its business absorbed or ...
PLX : Summary for Protalix BioTherapeutics, Inc. - Yahoo Finance
Protalix BioTherapeutics, Inc. (PLX)
NYSE MKT - NYSE MKT Delayed Price. Currency in USD
Add to watchlist
|Day's Range||1.06 - 1.16|
|52 Week Range||0.26 - 1.51|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-4.00|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|